Searchable abstracts of presentations at key conferences on calcified tissues

ba0003pp302 | Osteoporosis: treatment | ECTS2014

Comparison of osteosarcoma incidence between abaloparatide (BA058) and PTH (1--34) in long term rat studies

Hattersley Gary , Attalla Bassem , Varela Aurore , Smith Susan Y

It has been previously reported that prolonged treatment with rhPTH(1–34) or rhPTH(1–84) in rats is associated with the development of bone neoplasms including osteosarcomas. However, to date there has been no evidence of an increased osteosarcoma risk of in patients treated with rhPTH(1–34) or rhPTH(1–84), or in diseases associated with chronic PTH elevation. Abaloparatide (ABL) is a novel analog of PTHrP(1–34) currently being developed as a treatment...

ba0003pp352 | Osteoporosis: treatment | ECTS2014

Abaloparatide (BA058), a novel human PTHrP analog, restores bone mass and strength in the aged osteopenic ovariectomized cynomolgus monkey

Hattersley Gary , Doyle Nancy , Varela Aurore , Guldberg Robert E , Smith Susan Y

Abaloparatide (ABL) is a novel analog of hPTHrP (1–34) in clinical development for treatment of osteoporosis. This study evaluated the long-term effects of ABL on BMD and bone strength in aged osteopenic, ovariectomized (OVX) monkeys. Four groups of ≥9-year-old female cynomolgus monkeys underwent OVX and one group underwent Sham surgery. After a 9-month bone depletion period, increases in bone markers and decreases in BMD by DXA and pQCT were observed for OVX groups...